Intracellular Delivery of the p38 Mitogen-Activated Protein Kinase Inhibitor SB202190 [4-(4-Fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)1 H-imidazole] in Renal Tubular Cells: A Novel Strategy to Treat Renal Fibrosis
Jai Prakash(Radboud University Nijmegen), Robbert J. Kok(Utrecht University), Vinay Saluja(University of Groningen), M. Lacombe(Université du Québec à Rimouski), Robert H. Henning(University Medical Center Groningen), Johannes H. Proost(University of Groningen), Klaas Poelstra(University of Groningen), Frits Moolenaar(University of Groningen), Maria Sandovici(University Medical Center Groningen), Martin H. de Borst(University Medical Center Groningen), Dirk K. F. Meijer(University of Groningen), Harry van Goor(University Medical Center Groningen), Gÿorgý Kéri(Semmelweis University), Roel Q.J. Schaapveld(The Netherlands Cancer Institute)
Cited by 57
Related Papers
Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine
|Proceedings of the National Academy of Sciences|1997|884
RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature
|Drug Resistance Updates|2005|461
Ligand-targeted particulate nanomedicines undergoing clinical evaluation: Current status
|Advanced Drug Delivery Reviews|2013|396
Criteria for definition of a complex abdominal wall hernia
|Hernia|2013|340
Diverse origins of the myofibroblast—implications for kidney fibrosis
|Nature Reviews Nephrology|2015|305